ABSTRACT Gout is an increasingly prevalent condition with high global burden of disease due to a myriad of factors, including population ageing, rising affluence, changes in dietary habits and higher rates of obesity and metabolic syndrome. While many cases of gout flares can be managed with standard anti‐inflammatory medications (colchicine, non‐steroidal anti‐inflammatory drugs and/or corticosteroids), increasingly, there are patients who are refractory, intolerant or unsuitable (due to associated cardiometabolic conditions) for such treatments – whom we define as the “difficult‐to‐treat” cases. In this article, we sought to provide a practical approach to treating such cases of complex and refractory gout flares, through a simple 4A acronym (consider A lternate diagnosis, use of A nakinra and other IL‐1 receptor antagonists, A CTH injections and A djuvant measures).
Ng et al. (Sat,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: